Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 (2025/2026 formulation) in children 5-11 years at high risk for severe COVID-19
NCT07222384Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 3 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Oct 2025; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07222384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07222384.